



Webinar

How much does it cost to develop a new medicine? Public Versus Private Investments in the TB Drug Bedaquiline

Dzintars Gotham, Lindsay McKenna

26 March 2020

Q&A Session with the Participants

From Valerie Laigle

What do you mean by equally RandD cost?

From Marcela Vieira

Hello everyone, please select “all panelists and attendees” in the “to” box when sending your questions and comments.

From Ezio Távara

Thanks. Pls clarify better the concept of these “tax credits” to pharmaceutical companies.

From Ezio Távara

We can also assume all pre-clinic expenses are public funding, correct?

From Olena Wagner

Is there is a good reason why pre-clinical trials and operational expenses of public trial partners were not taken into account? Question to Dis. Thank you.

From Elin Svensson

I'm curious to how TB Alliance defends to NOT share their costs?

From Carlos R Olarte

How typical is this compound development compared to the development of other compounds where there is a lower participation of public investment? For example, can we say the Tufts studies are examining different, more traditional cases?

From Komakech Job

What's the figure from Africa in regards to public spending on R&D on TB medicine

From Michael Ssemakula

Thanks Gothan, if we have a significant public funding towards new medicines invention/development, why are the governments failing to develop functional and competitive global markets to address monopolies in the medicines sector over certain medicines, other health products and medical technologies?

From Olivier Wouters

Thanks, Dzintars and Lindsay, for very interesting presentations. Colleagues and I recently published a study in JAMA in which we presented a competing estimate to the Tufts figures using only publicly available data. We found the lack of R&D cost transparency very frustrating (and how much they benefitted from public sector investments and subsidies). How do you think we can encourage or demand transparency? What legislative changes are needed, what is the role of international organizations, what formats can R&D data be made available, to whom, etc.?

From Marcela Vieira

Thank you for the presentation. Lindsay, you mentioned that access conditions in public funding are still pretty much a theory. Was there any specific provisions applied to bedaquiline or any other TB drug you are aware of?

From Paul Wasswa

Lindsay, How has TB action based advocacy enhanced access to bedaquiline in South Africa considering costs invested in clinical trials by J&J?

From Michael Ssemakula

Thanks Lindsay. Now that we have the transparency resolution (anchored on access to medicines roadmap 2012-2023) which was launched last year at the previous World Health Assembly. Do we see this conversation around transparency going forward turning into reality especially on information concerning price differentiation, R&D, patent landscapes and clinical trials on medicines across countries?

From Ezio Távora

I assume the pre-clinical studies were conducted in universities and public institutions, therefore with public money... hard to think they were developed by private companies

From Temmy Sunyoto

1) Was there any kind of 'different' phase in the drug development process of BDQ, e.g where there is public and private collaboration, instead of the typical scenario where public entities doing (phase 3) trial with the originator donating the drugs for trials? 2) BDQ is first line treatment now, do you think worth doing similar analysis for drugs that are perhaps not that acutely important (even beyond TB)?

From Alex Kong

Thank you both for your presentations. I have a question for Diz: In the Drugs for Neglected Diseases initiative's 15-year report, they published the R&D costs to take candidates forward to clinical testing and beyond, including Fexinidazole (approved in 2018). The cost for the development of fexinidazole and projected cost of another candidate for sleeping sickness are below 60 million euros. Do you think that a general corrective ratio could be established (as was done in your BDQ study to compare public versus private funding) as a way to 'compare apples to apples' that could strip away capitalized/risk-adjusted costs, or would this likely differ substantially between different diseases/product types?

From Bruce Tushabe

Thanks a great deal for the presentations Gotham and Lindsay. Lindsay, what about the impact of the USD1 a day campaign? Is J&J reducing the price of BDQ?

From Krisantha Weerasuriya

A quick comment - all the post-approval trials (funded by public) of BDQ shows that it's place in TB has been clearly delineated. Compare that with other new approvals where post approval studies are few and far between.

From Marcela Vieira

For those interested in joining the TAG/MSF webinar on Xpert test mentioned by Lindsay, it is taking place on Friday, 3 April at 9am New York/ 3pm Geneva & Cape Town/ 6:30pm Delhi, using the following link <https://zoom.us/j/755611338>

From Marcela Vieira

The Knowledge Network has published a research synthesis on costs of pharmaceutical R&D, which is available at <https://www.knowledgeportalia.org/cost-of-r-d>

From Marcela Vieira

And there is also a research synthesis on public funding of pharmaceutical R&D available at <https://www.knowledgeportalia.org/public-funding-of-r-d>